INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – Should You Buy?

Shares of INmune Bio, Inc. (NASDAQ:INMB) rose 1.7% during trading on Tuesday . The stock traded as high as $4.93 and last traded at $4.88. Approximately 131,907 shares were traded during trading, a decline of 20% from the average daily volume of 165,580 shares. The stock had previously closed at $4.80.

Analyst Ratings Changes

Several analysts have recently issued reports on INMB shares. Scotiabank started coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price on the stock. Raymond James started coverage on shares of INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 target price on the stock. Finally, Alliance Global Partners started coverage on shares of INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock.

INmune Bio Stock Up 1.7 %

The firm has a market cap of $108.19 million, a price-to-earnings ratio of -2.24 and a beta of 1.85. The company’s 50-day moving average price is $5.37 and its 200-day moving average price is $7.18.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same quarter last year, the business earned ($0.48) EPS. Analysts predict that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Raymond Joseph Tesi bought 15,380 shares of INmune Bio stock in a transaction on Thursday, September 12th. The shares were bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the completion of the purchase, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. This trade represents a 1.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO David J. Moss bought 10,000 shares of INmune Bio stock in a transaction on Monday, September 30th. The shares were purchased at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 33,070 shares of company stock worth $200,087. 35.20% of the stock is owned by insiders.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors have recently bought and sold shares of INMB. Financial Advocates Investment Management raised its stake in INmune Bio by 17.4% during the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 2,000 shares during the period. Jane Street Group LLC purchased a new position in INmune Bio during the third quarter worth about $79,000. Sanctuary Advisors LLC purchased a new position in INmune Bio during the third quarter worth about $113,000. Rhumbline Advisers purchased a new position in INmune Bio during the second quarter worth about $121,000. Finally, Barclays PLC raised its stake in shares of INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after acquiring an additional 24,906 shares during the period. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.